<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2948">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716998</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MCS-01</org_study_id>
    <nct_id>NCT04716998</nct_id>
  </id_info>
  <brief_title>Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19</brief_title>
  <official_title>A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BonusBio Group Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BonusBio Group Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label clinical study to evaluate the safety and the efficacy of MesenCure, an&#xD;
      allogeneic cell therapy product, for the treatment of the pulmonary manifestations in COVID19&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: The IV administration of MesenCure is safe under the following conditions:&#xD;
      in subjects hospitalized with COVID19 moderate to severe disease, defined upon clinical&#xD;
      situation and radiologic findings.&#xD;
&#xD;
      Secondary endpoint: The IV administration of MesenCure is efficacious under the following&#xD;
      conditions:&#xD;
&#xD;
      Clinical parameters: Health questionnaire, respiratory rate, heart rate, blood pressure, RA&#xD;
      O2 saturation, hospitalization duration.&#xD;
&#xD;
      ______________________________________________________ Laboratory findings: leukocyte and&#xD;
      lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels.&#xD;
&#xD;
      ______________________________________________________ Radiologic findings: pulmonary&#xD;
      infiltrates, pleural effusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Mesencure</measure>
    <time_frame>30 days</time_frame>
    <description>No treatment-related adverse reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in RA-O2 saturation</measure>
    <time_frame>14 days</time_frame>
    <description>Elevation to 94% and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevation of lymphocytes level</measure>
    <time_frame>14 days</time_frame>
    <description>Elevation compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of CRP</measure>
    <time_frame>14 days</time_frame>
    <description>Reduction compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of health questionnaire</measure>
    <time_frame>21 days</time_frame>
    <description>Improvement compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced hospitalization duration</measure>
    <time_frame>30 days</time_frame>
    <description>Reduced compared to clinical site matching historical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in pulmonary infiltrates/ pulmonary congestion</measure>
    <time_frame>30 days</time_frame>
    <description>Improvement compared to day 0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MesenCure treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical interventions:&#xD;
Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.&#xD;
Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MesenCure</intervention_name>
    <description>Three administrations of MesenCure in addition to standard care</description>
    <arm_group_label>MesenCure treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are able and agree to sign informed consent form before any study-specific&#xD;
             procedure.&#xD;
&#xD;
          2. Males or females, age range 18-80.&#xD;
&#xD;
          3. Female subjects are eligible only if of non-child bearing potential.&#xD;
&#xD;
          4. Documented COVID19&#xD;
&#xD;
          5. O2 Saturation of ≤93%&#xD;
&#xD;
          6. Stable hemodynamic condition (blood pressure of systolic &lt;180mm Hg and diastolic&#xD;
             &lt;110mm Hg)&#xD;
&#xD;
          7. Evidence of COVID19-related pulmonary infiltrates on chest X-ray/thoracic tomography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Pregnant or breast-feeding females.&#xD;
&#xD;
          2. History of drug abuse.&#xD;
&#xD;
          3. Heavy smokers (above 2 packages a day).&#xD;
&#xD;
          4. Subjects incapable of giving consent.&#xD;
&#xD;
        Background medical conditions:&#xD;
&#xD;
          1. Known history of any significant medical disorder, which in the investigator's&#xD;
             judgment contraindicates the subject's participation.&#xD;
&#xD;
          2. History of significant heart diseases, renal failure (estimated GFR of &lt;30 ml/min/1.73&#xD;
             m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B&#xD;
             or C).&#xD;
&#xD;
          3. Known autoimmune diseases.&#xD;
&#xD;
          4. Received any investigational drug within 30 days prior to screening day (Visit 1)&#xD;
             (Remdesivir is not considered investigational, and is not an exclusion criteria).&#xD;
&#xD;
          5. Immunocompromised condition from any reason, at screening.&#xD;
&#xD;
          6. Abnormal clinically significant laboratory test findings, as per the investigator's&#xD;
             judgment.&#xD;
&#xD;
          7. Poorly controlled diabetic subjects (HbA1c &gt; 9%).&#xD;
&#xD;
          8. Known active lung malignancy.&#xD;
&#xD;
        Concomitant treatment:&#xD;
&#xD;
          1. Currently treated with Immunosuppressive agents other than corticosteroids used for&#xD;
             treating COVID19.&#xD;
&#xD;
          2. Treatment for cancer (i.e. chemotherapy or radiotherapy treatment) within the last 12&#xD;
             months.&#xD;
&#xD;
        Hypersensitivity:&#xD;
&#xD;
          1. Known history of hypersensitivity to Dextran-40 (HypoThermosol®).&#xD;
&#xD;
          2. Known history of hypersensitivity to Human Serum Albumin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shadi Hamoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vered Kivity, PhD, MBA</last_name>
    <phone>972-73-2067154</phone>
    <email>veredki@bonus-bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shadi Hamoud, MD</last_name>
      <phone>972-4-7773097</phone>
      <email>s_hamoud@rmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

